Key terms
About VYGR
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VYGR news
Mar 19
9:53am ET
Snowflake, MongoDB downgraded to Sell: Wall Street’s top analyst calls
Mar 19
6:17am ET
Voyager Therapeutics: A Buy Rating on Breakthrough CNS Gene Therapy Innovations and Strategic Growth Potential
Mar 19
6:05am ET
Voyager Therapeutics initiated with a Buy at H.C. Wainwright
Mar 13
7:19am ET
Voyager Therapeutics appoints Toby Ferguson as CMO
Mar 06
5:15pm ET
Voyager Therapeutics: A Strong Buy on CNS Gene Therapy Advances and Strategic Partnerships
Mar 06
5:05pm ET
Voyager Therapeutics initiated with a Buy at Citi
Mar 05
7:25am ET
Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst
Mar 01
7:48am ET
Oppenheimer Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
Mar 01
4:58am ET
Voyager Therapeutics Buy Rating Affirmed Amid Strong Pipeline and Financial Health
Mar 01
1:18am ET
Voyager Therapeutics’ Promising Outlook in Gene Therapy: A Strong Buy Recommendation
Feb 29
8:02am ET
Analysts Conflicted on These Healthcare Names: Immunocore Holdings (IMCR), Voyager Therapeutics (VYGR) and Castle Biosciences (CSTL)
Feb 28
6:10pm ET
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Warby Parker (WRBY)
Feb 26
7:16am ET
Voyager Therapeutics reports selection of gene therapy development candidate
Feb 20
7:06am ET
Voyager Therapeutics reports preclinical activity on tau silencing gene therapy
Jan 11
7:55am ET
Oppenheimer Keeps Their Buy Rating on Voyager Therapeutics (VYGR)
Jan 10
5:43am ET
Voyager Therapeutics: A Strong Buy on Technological Superiority and Strategic Financial Health
Jan 05
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Jan 04
10:59pm ET
Voyager Therapeutics 7.778M share Spot Secondary priced at $9.00
Jan 04
8:50pm ET
Voyager Therapeutics prices $100M offering at $9 per share, Bloomberg says
Jan 04
4:37pm ET
Voyager Therapeutics $100M Spot Secondary; price range $9.00-$9.50
Jan 04
4:16pm ET
Voyager Therapeutics announces $100M common stock offering
Jan 04
11:13am ET
Biotech Alert: Searches spiking for these stocks today
Jan 04
6:48am ET
Voyager Therapeutics price target raised to $18 from $16 at Oppenheimer
Jan 03
6:43am ET
Voyager Therapeutics price target raised to $18 from $15 at Baird
Jan 02
1:19pm ET
Wells Fargo upgrades Voyager on ‘highly validating’ Novartis deal
Jan 02
1:12pm ET
Wells Fargo upgrades Novartis on ‘highly validating’ Novartis deal
Jan 02
1:05pm ET
Voyager Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Jan 02
8:08am ET
M & A News: Voyager (NASDAQ:VYGR) Skyrockets on ~$1.3B Licensing Deal with Novartis (NYSE:NVS)
Jan 02
7:02am ET
Voyager Therapeutics enters capsid license agreement, collab with Novartis
No recent news articles are available for VYGR
No recent press releases are available for VYGR
VYGR Financials
Key terms
Ad Feedback
VYGR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VYGR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range